introduction and objectives: tuberculosis (tb) still remains a major health concern both in developing and developed countries. the rate of the liver injury due to anti-tb drugs in developed countries has been reported up to 4%. the goal of this study is to assess the rate and risk factors for anti-tuberculosis drug-induced liver injury (dili). also, a model has been designed to predict dili in...

the incidence of drug induced liver injury (dili) is about 1/1000 to 1/10000 among patients who receive therapeutic drug doses. drug induced hepatotoxicity is a major cause of acute and chronic liver disease. the severity of liver damage ranges from nonspecific changes in liver structure to acute liver failure, cirrhosis and liver cancer. some common agents that can cause liver injury are aceta...

Drug-induced liver injury (DILI) is an increasingly common cause of acute hepatitis. We examined clinical features and types of liver injury of 65 affected patients who underwent liver biopsy according DILI etiology. The major causes of DILI were the use of herbal medications (43.2%), prescribed medications (21.6%), and traditional therapeutic preparations and dietary supplements (35%). DILI fr...

The objectives of DILI WP3 were to qualify one or a set of new biomarkers with respect to: an early or earlier diagnosis of DILI as compared to current diagnostic rules the ability to predict DILI outcome, with particular emphasis on severe DILI/acute liver failure the prognosis and monitoring of progression and regression of DILI the differentiation between patients who incur true drug-induced...

Drug-induced liver injury (DILI) is an important clinical problem, which has received more attention in recent decades. It can be induced by small chemical molecules, biological agents, traditional Chinese medicines (TCM), natural medicines (NM), health products (HP), and dietary supplements (DS). Idiosyncratic DILI is far more common than intrinsic DILI clinically and can be classified into he...

Drug-induced liver injury (DILI) has become a leading cause of severe liver disease and withdrawal of an approved drug from the market. DILI accounts for acute liver failure, liver transplantation or death in the United States today. A recent retrospective study indicates that the risk of DILI is enhanced when the administered daily dosage is higher than 50 mg or when the drug undergoes signifi...

UNLABELLED Drug-induced liver injury (DILI) is considered to be a diagnosis of exclusion. Liver biopsy may contribute to diagnostic accuracy, but the histological features of DILI and their relationship to biochemical parameters and outcomes are not well defined. We have classified the pathological pattern of liver injury and systematically evaluated histological changes in liver biopsies obtai...

Patients with idiosyncratic drug-induced liver injury (DILI) can pose substantial diagnostic, prognostic, and therapeutic challenges to the practicing gastroenterologist. The presentation of DILI may vary from asymptomatic liver enzyme elevation to acute liver failure. Although most DILI resolves following drug discontinuation, up to 20% of patients progress to chronic DILI further challenging ...

The spectrum of drug-induced liver injury (DILI) is both diverse and complex. The first step in diagnosis is a suspicion of DILI based on careful consideration of recent comprehensive reports on the disease. There are some situations in which the suspicion of DILI is particularly strong. Exclusion of other possible etiologies according to the pattern of liver injury is essential for the diagnos...

Drug-induced liver injury (DILI) is a rare but potentially life threatening adverse drug reaction. DILI may mimic any morphologic characteristic of acute or chronic liver disease, and the histopathologic features of DILI may be indistinguishable from those of other causes of liver injury, such as acute viral hepatitis. In this review article, we provide an update on causative agents, clinical f...